Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 41Glioma 22Brain Neoplasms 14Astrocytoma 11Neuroblastoma 10Gliosarcoma 10Neoplasms 8Sarcoma, Ewing 7Rhabdomyosarcoma 6Sarcoma 5Recurrence 5Oligodendroglioma 5Medulloblastoma 4Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Diffuse Intrinsic Pontine Glioma 3Wilms Tumor 2Pancreatic Neoplasms 2Osteosarcoma 2Melanoma 2Lymphoma, Follicular 2Hepatoblastoma 2Central Nervous System Neoplasms 2Spinal Cord Neoplasms 1Somatostatinoma 1Rhabdoid Tumor 1Refractory Solid Tumors 1Pyloric Stenosis, Hypertrophic 1Prostatic Neoplasms 1Pheochromocytoma 1

Interventions

trastuzumab deruxtecan 1sacituzumab govitecan 1Temozolomide 1Social Determinants of Health 1Methylprednisolone 1Irinotecan 1Cefixime 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Temozolomide × 90 days × Clear all
NCT00093353 2026-04-14

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
30 enrolled
CNS

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡